SCHEMBL2648950

SCHEMBL2648950

CC(C)c1ccc(C(CC(=O)c2ccc(C3CCCCC3)cc2)C(=O)c2ccc(C(=O)NCC(O)C(=O)O)cc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GCGR P47871 9/20 0.48
GIPR P48546 7/20 0.48
BCL2L1 Q07817 2/20 0.43
MCL1 Q07820 2/20 0.43
POLB P06746 1/20 0.43
APAF1 O14727 1/20 0.43
HAO1 Q9UJM8 1/20 0.42
SERPINE1 P05121 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
PPARG P37231 1/20 0.38
PPARD Q03181 1/20 0.38
PPARA Q07869 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2648952 1.00 GCGR (0.48) GCGRGIPRBCL2L1MCL1POLB
SCHEMBL6916489 0.91 GCGR (0.53) GCGRGIPRBCL2L1MCL1APAF1
SCHEMBL6916484 0.91 GCGR (0.53) GCGRGIPRBCL2L1MCL1APAF1
SCHEMBL2645898 0.90 GCGR (0.46) GCGRGIPRBCL2L1MCL1APAF1
SCHEMBL2645893 0.90 GCGR (0.46) GCGRGIPRBCL2L1MCL1APAF1
SCHEMBL2647125 0.86 CYP2D6 (0.45) GCGRBCL2L1MCL1POLBAPAF1
SCHEMBL2665144 0.86 GCGR (0.51) GCGRGIPRBCL2L1MCL1APAF1
SCHEMBL2665072 0.81 GCGR (0.47) GCGRGIPRBCL2L1MCL1POLB
SCHEMBL2665061 0.81 GCGR (0.55) GCGRGIPRBCL2L1MCL1APAF1
SCHEMBL2647235 0.81 GCGR (0.43) GCGRGIPRBCL2L1MCL1APAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1463715-A1 NOVEL GLUCAGON ANTAGONISTS NOVO NORDISK A/S (DK) 2004-10-06 EP disclosed
US-6762318-B2 CARBOXYLIC ACID OR TETRAZOLE DERIVATIZED SECONDARY AMIDES; ORAL ADMINISTRATION NOVO NORDISK A/S (DK) 2004-07-13 US disclosed
US-20030236292-A1 Stimulant releasing glucose from liver cells; antidiabetic agents PFIZER INC 2003-12-25 US disclosed
WO-2003048109-A1 NOVEL GLUCAGON ANTAGONISTS NOVO NORDISK A/S (DK) 2003-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236292-A1 Stimulant releasing glucose from liver cells; antidiabetic agents GPR119, GLP1R, GIPR GCGR 4/4885GIPR 3/4885BCL2L1 2216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.